Mesenchymal Stromal Cell Therapy for COVID-19 Acute Respiratory Distress Syndrome: A Double-Blind Randomised Controlled Trial

Scientists conducted a randomised, placebo-controlled, double-blind clinical trial to assess the efficacy and safety of one bone marrow-derived MSC infusion in twenty patients with moderate to severe ARDS caused by COVID-19.